Pieces of Interest from COMP for the week of February 14 – Lifecyle Licensing/MET-PET useful for diagnosing childhood brain tumors/COMP ASM 2022
Published on:
- Lifecycle licensing is open for business – read about it in the January issue of InterACTIONS.
- Brain PET imaging with carbon-11 methionine (C-11 MET) may be an effective new approach for identifying developmental brain tumors in children and adolescents, according to a study published February 7 in PLOS One.
- Join us in Québec City for the 2022 COMP ASM – “Science Unplugged” June 22 – 25, 2022!
COMP is excited to welcome you back for an exciting face-to-face program. Get unplugged and participate in sessions focusing on advances in the science of medical physics. Call for CE Sessions, Workshops, Scientific, and YIS abstracts opens this month! Stay tuned for more details coming soon! Come early and join international colleagues at the IC3DDose – an international conference on 3D dosimetry!
Published on February 14, 2022
Related Articles
Pieces of Interest from COMP for the Week of September 25 – Deep-Learning Model Detects More Breast Cancers in High-Risk Women/Executive Director Report/COMP Career Page
A mammogram-based deep learning model can identify more breast cancers at screening MRI than traditional risk assessment models, according to a study published September 19...
Pieces of Interest from COMP for the Week of September 18 – Novel Machine Learning Approach Reveals The Hidden Origins Of Cancers/Message from the CCPM President/IDMP 2023
A research collaboration from MIT and Dana-Farber Cancer Institute have harnessed the power of machine learning to develop a computational model that can predict the...
Pieces of Interest for the week of Monday September 11, 2023 – CNSC Innovation Grant/PROSPECT Trial Expands Treatment Options for Patients with Resectable Rectal Cancer/Message from the COMP President
COMP is pleased to announce a refresh of the Canadian Nuclear Safety Commission (CNSC) funded Innovation Grant. Following consultation with COMP members and the research...
